Compare FULT & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULT | PBLS |
|---|---|---|
| Founded | 1882 | N/A |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | N/A | 2026 |
| Metric | FULT | PBLS |
|---|---|---|
| Price | $24.61 | $30.15 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $21.75 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 545.1K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.39 | N/A |
| Revenue Next Year | $5.52 | N/A |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $25.56 |
| 52 Week High | $25.23 | $33.65 |
| Indicator | FULT | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 56.09 |
| Support Level | $23.51 | $26.96 |
| Resistance Level | $24.71 | $30.90 |
| Average True Range (ATR) | 0.51 | 2.47 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 63.27 | 51.59 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.